Medical Oncology

Daniel James George, MD

Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-4615
Email address daniel.george@duke.edu

Education and Training

  • Fellow in Medical Oncology, Medicine, Johns Hopkins University, 1995 - 1998
  • Medical Resident, Medicine, Johns Hopkins University, 1992 - 1995
  • M.D., Duke University, 1992

Grants

Publications

Gupta, Santosh, Daniel H. Hovelson, Gabor Kemeny, Susan Halabi, Wen-Chi Foo, Monika Anand, Jason A. Somarelli, et al. “Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.” Genes Chromosomes Cancer 59, no. 4 (April 2020): 225–39. https://doi.org/10.1002/gcc.22824.

PMID
31705765
Full Text

George, Daniel J., Susan Halabi, Patrick Healy, Darius Jonasch, Monika Anand, Julia Rasmussen, Sarah Y. Wood, Charles Spritzer, John F. Madden, and Andrew J. Armstrong. “Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.” Urol Oncol 38, no. 3 (March 2020): 79.e15-79.e22. https://doi.org/10.1016/j.urolonc.2019.08.015.

PMID
31522863
Full Text

Ramaswamy, Krishnan, Stanislav Lechpammer, Jack Mardekian, Ahong Huang, Neil M. Schultz, Rickard Sandin, Li Wang, Onur Baser, and Daniel J. George. “Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.” Adv Ther, February 28, 2020. https://doi.org/10.1007/s12325-020-01260-x.

PMID
32112280
Full Text

Kinsey, Emily N., and Daniel George. “Can I Get a Multidisciplinary Consult, Please? Systemic Immunotherapy and the Timing of Cytoreductive Nephrectomy.” Eur Urol Focus 6, no. 1 (January 15, 2020): 9–10. https://doi.org/10.1016/j.euf.2019.05.013.

PMID
31147262
Full Text

Rini, Brian I., Dena Battle, Robert A. Figlin, Daniel J. George, Hans Hammers, Tom Hutson, Eric Jonasch, et al. “The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).” J Immunother Cancer 7, no. 1 (December 20, 2019): 354. https://doi.org/10.1186/s40425-019-0813-8.

PMID
31856918
Full Text

Holl, Eda K., Megan A. McNamara, Patrick Healy, Monika Anand, Raoul S. Concepcion, Coleman D. Breland, Igor Dumbudze, et al. “Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.” Prostate Cancer Prostatic Dis 22, no. 4 (December 2019): 588–92. https://doi.org/10.1038/s41391-019-0144-3.

PMID
30980027
Full Text

George, Daniel J., Susan Halabi, Patrick Healy, Ian Barak, Carolyn Winters, Monika Anand, Rhonda Wilder, et al. “Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.” Prostate 79, no. 15 (November 2019): 1752–61. https://doi.org/10.1002/pros.23899.

PMID
31497882
Full Text

Zhu, Jason, Matthew Tucker, Daniele Marin, Rajan T. Gupta, Patrick Healy, Michael Humeniuk, Casey Jarvis, et al. “Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.” Urol Oncol 37, no. 11 (November 2019): 813.e1-813.e9. https://doi.org/10.1016/j.urolonc.2019.06.015.

PMID
31327751
Full Text

Flaifel, Abdallah, Wanling Xie, David A. Braun, Miriam Ficial, Ziad Bakouny, Amin H. Nassar, Rebecca B. Jennings, et al. “PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.” Clin Cancer Res 25, no. 20 (October 15, 2019): 6080–88. https://doi.org/10.1158/1078-0432.CCR-19-1135.

PMID
31371341
Full Text

Freedland, Stephen J., Lauren Howard, Jenifer Allen, Jordan Smith, Jennifer Stout, William Aronson, Brant A. Inman, et al. “A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.” Prostate Cancer Prostatic Dis 22, no. 3 (September 2019): 428–37. https://doi.org/10.1038/s41391-019-0126-5.

PMID
30664736
Full Text

Pages